Physician profile
Chad Schroeder
NPI 1861761199
$845.67
in general payments reported to CMS, 2019-2025
11 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $167 · 2022: $110 · 2023: $84.72 · 2024: $93.13 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $550 · Education: $18.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.44 |
| Education | $18.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $224.66 | 2021-2025 | Saphnelo |
| Amgen INC. | $224.31 | 2025 | Tavneos, Otezla, Evenity |
| Glaxosmithkline, LLC. | $121.51 | 2021 | |
| Novartis Pharmaceuticals Corporation | $66.87 | 2025 | |
| Lundbeck LLC | $56.83 | 2022 | |
| Janssen Biotech, INC. | $52.99 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $27.33 | 2021 | |
| Horizon Therapeutics Plc | $23.98 | 2023 | Krystexxa |
| Abbvie INC. | $20.42 | 2025 | |
| Ucb, INC. | $13.60 | 2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $13.17 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Schroeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.